A Real World Study of Sacituzumab Govitecan

This study is observing how sacituzumab govitecan (a targeted antibody-drug therapy) works in real-world practice for people with advanced triple-negative breast cancer or hormone receptor-positive, HER2-negative breast cancer that has stopped responding to prior treatments. **You may be eligible if...** - You are 18 or older - You have unresectable or metastatic triple-negative breast cancer and have received at least two prior systemic treatments (at least one for metastatic disease) - OR you have HR+/HER2-negative metastatic breast cancer with at least two prior lines of therapy for metastatic disease - Your general health status allows treatment **You may NOT be eligible if...** - You have not received prior required therapies - You have significant organ dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.